KCAS Bio has embarked on a global initiative to harmonize its spectral flow cytometry services across four labs in three countries, collaborating with Crux Biolabs and Cytek Biosciences. This effort ensures standardized flow cytometry services across sites in the U.S., Europe, and Australia. As trials increasingly span multiple regions, global…

We are thrilled to announce a major milestone in the evolution of our global clinical support services. After months of detailed planning, collaboration, and execution, we’ve successfully integrated spectral flow cytometry at our KCAS Bio sites in Philadelphia, PA, USA; Lyon, France; and Crux Biolabs, our…

Clinical sample kitting plays a vital role in drug development projects. It requires meticulous attention to detail and the experience necessary to ensure that each kit is crafted according to precise specifications. A well-organized clinical kit can be the difference between smooth operations and costly delays. At KCAS Bio, we…

KCAS Bio is excited to announce our participation in several premier conferences throughout the United States this fall. These events bring together experts, innovators, and leaders in pharmaceuticals, biotechnology, and clinical research to exchange insights, explore the latest technologies, and drive the future of scientific discovery. As a trusted provider…

When you examine how to develop and validate/qualify a Biodistribution assay by PCR…

KCAS Bio is excited to announce our participation in several key conferences throughout the world. These events present invaluable opportunities for collaboration, innovation, and the sharing of industry insights. As a leading provider of bioanalytical services, KCAS Bio is committed to engaging with thought leaders, scientists, and professionals worldwide to…

In both preclinical and clinical studies, evaluating immunogenicity—an immune system’s response to a foreign substance—is a critical factor. Anti-drug antibody (ADA) assays play a pivotal role in this evaluation, helping researchers and pharmaceutical companies determine how the immune system reacts to therapeutic drugs. But what exactly is immunogenicity? Simply put,…

The Role of Pharmacokinetics (PK) in Drug R&D Pharmacokinetics (PK) is defined as the study of the fate of a new therapeutic entity (NTE) after it is administered into the body of animals or humans. It involves understanding how the drug is absorbed, distributed, metabolized, and eliminated (ADME). Essentially, PK…

The exploration of Targeted Protein Degraders (TPD) as a therapeutic modality began over twenty years ago. Since then, research and development in this field have steadily advanced. Starting in 2019, rationally designed small molecule TPDs entered clinical trials. This innovative therapeutic modality utilizes the cells’ endogenous protein degradation machinery to…

Preclinical formulation analysis supports toxicity studies before and after the investigational new drug application (IND). Multiple analytical studies support drug development progression beyond the IND stage. KCAS Bio performs analytical studies for a variety of clients. How Does KCAS Bio Perform Preclinical Formulation Analysis? KCAS Bio has completed numerous studies…

Cell and Gene Therapies (CGTs) are types of treatment that uses cellular or genetic material with the goal of treating a disease or a disordered. Often it can be a combination of cell and gene therapies, which is the case for Chimeric antigen receptor T cells (CAR T-Cells). There are…

In today’s drug development efforts, Research and Development has increasingly expanded to include multi-country strategies. Over time, pharmaceutical and biotech companies have made substantial impact on economies where development work is conducted, and some countries have developed strategies (i.e. Australia) to attract this lucrative market via financial incentives and offering…